Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06450886 · ClinicalTrials.gov registry record · Phase 2
Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis
A Phase 2 study of Inclusion Body Myositis (IBM), sponsored by Abcuro.
- Active
- Registry status
- Phase 2
- Development phase
- 270
- Enrollment target
- 20
- Study locations
NCT06450886 is a Phase 2 study of Inclusion Body Myositis (IBM) that is active but no longer recruiting, run by Abcuro. The registered enrollment target is 270 participants. The trial reports 20 study locations across 13 states.
The verdict
NCT06450886, a Phase 2 study of Inclusion Body Myositis (IBM), is active but no longer recruiting, sponsored by Abcuro.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 270 participants
- Enrollment target
- 20
- Study locations
Study Summary
ABC008-IBM-202 is an open-label, multicenter study to evaluate the safety and efficacy of long-term administration of ulviprubart (ABC008) in subjects with IBM who have completed either Study ABC008-IBM-101 or Study ABC008-IBM-201. Subjects may be enrolled in this study if they meet study eligibility criteria and: * Have completed the Part 2 (Multiple Ascending Dose \[MAD\]) End of-Treatment (EOT) Visit in Study ABC008-IBM-101; subjects who continued further on into Part 3 of the study (MAD Extension) prior to enrolling in this study are also eligible; OR * Have completed the Week 80 Follow-up Visit in Study ABC008-IBM-201.
Conditions Studied
Interventions
- DRUG Ulviprubart (ABC008)
Study Locations (20)
Pennsylvania
- Penn State Health Milton S. Hershey Medical Center - Hershey
- University of Pennsylvania - Philadelphia
- UPMC Arthritis and Autoimmunity Center, Falk Clinic - Pittsburgh
Texas
- Austin Neuromuscular Center - Austin
- Texas Neurology - Dallas
- Nerve and Muscle Center of Texas - Houston
California
- University of California Irvine Medical Center (UCIMC) - Amyotrophic Lateral Sclerosis (ALS) and Neuromuscular Center - Irvine
- Keck Hospital of USC - Los Angeles
Massachusetts
- Neuromuscular Diagnostic Center - Massachusetts General Hospital - Boston
- Brigham and Womens Hospital - Boston
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
- Ohio State University Wexner Medical Center - Columbus
Arizona
- Neuromuscular Research Center - Phoenix
Connecticut
- Yale School of Medicine - New Haven
New York
- Hospital for Special Surgery - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2024-10-21 |
| Est. Completion | 2029-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06450886
The ClinicalTrials.gov registry entry for NCT06450886 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 270 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abcuro, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Inclusion Body Myositis (IBM) appearing as the primary indexed condition, and to 1 intervention - of which Ulviprubart (ABC008) is the first listed.
NCT06450886 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Pennsylvania, Texas, California.
Frequently Asked Questions
What is clinical trial NCT06450886 about?
NCT06450886 is a clinical study titled "Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis". ABC008-IBM-202 is an open-label, multicenter study to evaluate the safety and efficacy of long-term administration of ulviprubart (ABC008) in subjects with IBM who have completed either Study ABC008-IBM-101 or Study ABC008-IBM-201. Subjects may be enrolled in this study if they meet study eligibilit...
What is the current status of trial NCT06450886?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 270 participants. The study started on 2024-10-21. Estimated completion is 2029-04.
What conditions does trial NCT06450886 study?
This clinical trial studies the following conditions: Inclusion Body Myositis (IBM).
What interventions are being tested in trial NCT06450886?
The interventions under investigation include: Ulviprubart (ABC008) (DRUG).
Who is sponsoring clinical trial NCT06450886?
This trial is sponsored by Abcuro, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06450886 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.